Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis

This study is part of the National Institute of Mental Health's Recovery After an Initial
Schizophrenia Episode (RAISE) Project. The RAISE Project seeks to fundamentally change the
trajectory and prognosis of schizophrenia through coordinated and aggressive treatment in
the earliest stages of illness. This study, the RAISE Connection Program, is one of the two
independent research studies that NIMH has funded to conduct the NIMH RAISE Project. The
Connection Program is being supported in whole or in part with Federal funds from the
American Recovery and Reinvestment Act of 2009 and the NIMH, National Institutes of Health,
Department of Health and Human Services. The Connection Program aims to to assess the
effectiveness of a Team-based intervention for individuals with a first psychotic episode,
observing outcomes over time for our study participants. When tracking outcomes, the
Connection Program will make comparisons with what is known about the natural history of
untreated first episode of psychosis as well as usual care outcomes from other experimental
studies.

This study is for people who have experienced symptoms such as hallucinations, unusual
thoughts or beliefs, or disorganized thinking for the first time during the past two years.
Without treatment, many people have a difficult time with these symptoms, which can be very
upsetting and also make it hard to socialize, study, or work.

People have different wishes and needs, and it is not clear what combination of treatments
and services is best for any one person. There are many possible treatments and services,
such as medications, talk therapy, case management, and school and job counseling. This
study will adapt and evaluate the impact of a comprehensive and integrated treatment
intervention for first episode psychosis to be delivered in real-world practice settings to
promote symptomatic recovery, minimize disability, and maximize social, academic, and
vocational functioning.

Participation in this study will last up to 2 years. At the baseline visit, participants
will be enrolled to receive the experimental intervention. During the study period,
participants will take part in research interviews every three to six months for a total of
6 interviews. Each of these research interviews will take 1.5 to 3 hours to complete.
Assessments of participants' health condition, overall function and illness severity,
employment status, academic performance, and social functioning will be conducted during
these research interviews. In addition to assessing functioning and illness severity, this
study will also address substance abuse and utilization of healthcare services. Participants
will also be measured for their height, weight and waist circumference.

Inclusion Criteria:

- Age range: 15-35 years old (16-35 years old in New York)

- Diagnosis of schizophrenia, schizoaffective and schizophreniform disorder, delusional
disorder, or psychosis not otherwise specified (NOS)

- Duration of psychotic symptoms > 1 week and < 2 years

- Ability to provide informed consent

- Ability to speak and understand English

- Anticipated availability to participate in the intervention for at least 1 year

Exclusion Criteria:

- Medical conditions which impair function independent of psychosis

- Other diagnoses associated with psychosis:

- Substance-induced psychotic disorder

- Psychotic affective disorder (major depressive or manic episode with psychotic
features)

- Psychotic disorder due to a general medication condition

- Mental retardation